p53-Tumor Suppression

The vast majority of p53-regulated genes are induced in response to various stress signals and are responsible for maintaining genetic stability, DNArepair, regulation of crucial cell-cycle check points, and finally induction of apoptosis. The activity of p53 is tightly controlled by two major negative regulators including murine double minute 2 (MDM2; EC 6.3.2.19) and 4 (MDM4 or MDMX) proteins. Human MDM2 and MDMX are structurally related and contain three well-conserved domains: an N-terminal domain (responsible for p53 binding), a zinc-finger domain (function largely unknown) and a C-terminal RING domain (responsible for formation of homo- and heterodimers). Additionally, the RING domain of MDM2 confers E3 ubiquitin ligase activity. Concentration/activity of p53 is kept at low level in unstressed cells. This is accomplished by three parallel mechanisms mediated by MDM2 and/or MDMX. First, MDM2 and MDMX bind the N-terminal transactivation domain (TAD) of p53, preventing thereby its interaction with the transcription machinery and resulting in the inhibition of p53-responsive gene expression. Second, MDM2/X proteins export p53 outside the nucleus into the cytoplasm where it can no longer activate transcription. Finally, MDM2 marks p53 for proteasomal degradation[1]. Many tumors overproduce MDM2 to impair p53 function. Therefore, restoration of p53 activity by inhibiting the p53–MDM2 binding represents an attractive novel approach to cancer therapy[2].


[1] K. Zak et al. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present). Exp. Opin. Ther. Pat. 2013, 23, 425-448.
[2] B.T. Vu, L. Vassilev. Small-Molecule Inhibitors of the p53-MDM2 Interaction. Curr. Top. Microbiol. Immun. 2011, 348, 151-172.

Items 31 to 60 of 87 total

per page
Page:
  1. 1
  2. 2
  3. 3
Axon ID Name Description From price
3765 DS-3032 Orally available, potent and selective inhibitor of the p53-MDM2 interaction Inquire
3732 HBX 41,108 Inhibitor of deubiquitinase USP7 €110.00
1643 HLI 373 HDM2 inhibitor €100.00
1538 JNJ 26854165 HDM2 inhibitor €105.00
1586 JNJ 26854165 dihydrochloride HDM2 inhibitor €105.00
2949 JNK inhibitor VIII Selective, ATP-competitive, and cell-permeable JNK inhibitor €105.00
2361 JNK-IN-8 Remarkably potent and selective covalent inhibitor of JNK €95.00
1367 KU-55933 ATM inhibitor €110.00
2319 L 002 Inhibitor of p300 HAT (KAT3B) and p53 acetylation €80.00
2820 LB-100 Specific, competitive inhibitor of PP2A €110.00
2273 LEE 011 Orally bioavailable and highly selective small-molecule inhibitor of CDK4/6 €80.00
2678 ML364 Inhibitor of the deubiquitinase USP2 €125.00
2695 NSC 23005 sodium Novel small molecule inhibitor of INK4C (p18(INK4C) or p18) €90.00
1402 NSC 348884 NPM inhibitor €120.00
1243 NSC 625987 CDK4 inhibitor €95.00
2966 NSC745887 DcR3 inhibitor €95.00
1585 Nutlin-3 MDM2 inhibitor (p53 specific) €95.00
1880 Nutlin-3a Inhibitor of MDM2 €95.00
1881 Nutlin-3b Less potent (+)-enantiomer of Nutlin-3 €90.00
3751 NVP-CGM097 Inhibitor of MDM2 Inquire
3752 NVP-CGM097 dihydrochloride Inhibitor of MDM2 Inquire
1416 NVP-TAE684 NPM-ALK inhibitor €50.00
2052 Palbociclib isethionate Orally active cyclin-dependent kinase (CDK4/6) inhibitor €125.00
3152 PAWI-2 Inhibitor which targets both Wnt signaling and ATM/p53 €120.00
1505 PD0332991 hydrochloride CDK4 and CDK6 inhibitor €85.00
1379 PF 477736 CHK1 inhibitor €70.00
3693 PF-06873600 CDK inhibitor (4, 6, and 8 specific) Inquire
3753 PF-07104091 Specific CDK2 inhibitor €140.00
3762 PF-07220060 Orally bioavailable and CDK4-Specific Inhibitor Inquire
2488 Piperlongumine Natural alkaloid with potent cytotoxic activity €65.00

Items 31 to 60 of 87 total

per page
Page:
  1. 1
  2. 2
  3. 3
Please wait...